In this podcast, PO CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguarda Cancer Centre, Milan, Italy) provide both a pathologist and medical oncologist perspective about the detection and treatment of TRK fusion-positive GI cancers, with a particular focus on colorectal cancer.
Penault-Llorca and Sartore-Bianchi start by explaining TRK fusion biology, the role as oncogenic drivers and briefly describe the two approved TRK inhibitors. They then discuss the challenges of finding patients harboring these fusions, referring to how enrichment strategies and predictors can aid identification in patients with GI cancers. Finally, they discuss key efficacy and safety data for larotrectinib and entrectinib, as well as mentioning second-generation products in development to tackle mechanisms of resistance.
In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to...
Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the...
In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical Oncologist from Antwerp...